An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 225-232

  Todisco, T ^a   Dal Farra, F ^b   Ciliberti, G ^c   Pirica, P ^d   Ghelfi, R ^e   Serra, G ^e   Paris, R ^f   Mancuso, I ^e   Cepparulo, Mario ^e  

^a Ospedale Silvestrini   (Italy)

^b San Bassiano Hospital   (Italy)

^c 2th Division of Pneumology   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e PFIZER INC   (United States)

^f Division of General Medicine   (Italy)

Author keywords

Azithromycin i.v. and oral; Combination therapy; Community acquired pneumonia

Indexed keywords

AZITHROMYCIN; SULTAMICILLIN;

ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INJECTION SITE PAIN; ITALY; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RELAPSE; SIDE EFFECT; SPUTUM CULTURE; STOMATITIS; SUPERINFECTION; SYMPTOMATOLOGY; THROMBOCYTHEMIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; X RAY;

EID: 44849111008     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.225     Document Type: Article

References (32)

1. Viegi G, Pistelli R, Cazzola M et al. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 2006; 100 (1): 46-55.
2. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
3. Shah PB, Giudice JC, Griesback R Jr, Morley TF, Vasoya A. The newer guidelines for the management of community-acquired pneumonia. J Am Osteopath Assoc 2004; 104 (12): 521-526.
4. Niedemnan MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730-1754.
5. Ruiz M, Ewig S, Marcos MA et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160 (2): 397-405.
6. Lieberman D, Schlaeffer F, Boldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51 (2): 179-184.
7. Gleason PP. The emerging role of atypical pathogens in community-acquired pneumonia.
8. Pharmacotherapy 2002; 22: 2S-11S.
9. Leroy O, Santre C, Beuscart C et al: A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21 (1): 24-31.
10. Socan M, Marinic-Fiser N, Kraigher A, Kotnik A, Logar M. Microbial aetiology of community-acquired pneumonia in hospitalised patients. Eur J Clin Microbiol Infect Dis 1999; 18 (11): 777-782.
11. Bates JH, Campbell GD, Barron AL et al: Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101: 1005-1012.
12. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10-21.
13. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother 1999; 33 (2): 218-228.
14. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91 (3A): 5S-11S.
15. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990; 25 (Suppl A): 123-126.
16. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10 (10): 872-877.
17. Kuzman I, Dakovic-Rode O, Oremus M, Banaszak AM. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J Chemother 2005; 17 (6): 636-642.
18. Cockburn J, Gibberd RW, Reidal, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J 1987; 295: 814-818.
19. Sanchez F, Mensa J, Martinez JA et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 2003; 36 (10): 1239-1245.
20. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
21. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164 (6): 637-644.
22. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006; 119 (10): 859-864.
23. Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006; 119 (10): 865-871.
24. Ramirez JA, Vargas S, Ritter GW et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-2454.
25. Restrepo MI, Mortensen EM, Pugh JA. Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28 (2): 346-351.
26. Plouffe J, Schwartz DB, Koiokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44 (7): 1796-1802.
27. Bohte R, van't Wout JW, Lobatto S et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14(3):182-187.
28. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17 (12):828-833.
29. Treadway G, Reisman A. Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. Int J Antimicrob Agents 2001; 18 (5): 427-431.
30. Romano A, Blanca M, Mayorga C, Venuti A, Gasbarrini G. Immediate hypersensitivity to penicillins. Studies on Italian subjects. Allergy 1997; 52 (1): 89-93.
31. Corrao G, Botteri E, Bagnardi V, Zambon A, Carobbio A, Falcone C, Leoni O. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Saf 2005; 14 (1): 31-40.
32. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43 (12): 1603-1611.